

# Innovation Brief

## Medical Technology Innovation Dynamic Purchasing System - Endosign

### Summary

#### Disruptive Innovation

This briefing introduces a disruptive innovation newly available via NHS Supply Chain: The Endosign. Reviewed by clinical specialists and supported by key stakeholders, this device offers a novel approach for early detection and monitoring of Barretts Oesophagus and oesophageal cancer as an alternative to Endoscopy. The Endosign is a minimally invasive capsule sponge device that enables safe and accessible cell collection with pathology testing included.

### Introduction

This document is intended to inform clinical stakeholders and procurement teams about innovative products that have undergone a clinical review and are now accessible through NHS Supply Chain.

Products featured in this brief may be classified as:

- Disruptive Innovations
  - A disruptive innovation is novel.
  - It should offer improvements compared to the existing provision of care.
  - The proposed format should not exist elsewhere (either within or beyond the health and care sector).

**Note:** While robust evidence or validated savings may not yet be available, early data and clinical insights support the potential for patient and system-level improvements.

### Departments / stakeholders for engagement

- NHS procurement teams.
- Endoscopy departments.
- Gastroenterology departments.
- Cancer services and teams.
- Primary care.
- Pathology departments.

### Opportunity

The Endosign presents an opportunity to enhance care by:

- Alternative option to endoscopy.
- Early detection.
- Enhanced patient experience.

# Innovation Brief

## Product overview

Endosign is a non-invasive, capsule sponge test used to screen for Barrett's oesophagus and early signs of oesophageal cancer in patients with chronic heartburn.



### Additional benefits:

- Improved patient experience and safety: the procedure is well-tolerated, quick, and non-invasive, whilst removing the anxiety associated with conventional endoscopic examinations.
- Increased access and efficiency: it can be administered in varied settings, including GP surgeries and local clinics, making it more accessible to patients.
- Reduced waiting lists by releasing capacity identifying patients who require a follow up endoscopy.

### Cautions:

- Alarm symptoms:
  - Dysphagia, dyspepsia and weight loss, dyspepsia and anaemia.
- Previous cancer of the oesophagus or treatment for oropharyngeal, oesophageal or gastro oesophageal.
- Patient known to have oesophageal varices or cirrhosis of the liver.
- Patient with a known anomaly of the oesophagus.
- Patients who have had a myocardial infarction in the last 3 months.

## Supply details

The product bundle includes: 10 Endosign cell collection device, 10 Endosign cell preservation kits and 10 Endosign diagnostic reports

Route - eDirect.

Supplier - Cytel Health.

Unit of Issue - box of 10.

Complete requirements in form on <https://www.supplychain.nhs.uk/dps>

## Supporting evidence / notes

Cytosponge for detecting abnormal cells in the oesophagus - NICE briefing:

<https://www.nice.org.uk/advice/mib240/resources/cytosponge-for-detecting-abnormal-cells-in-the-oesophagus-pdf-2285965626228421>

## Contact details

**Rob Campbell** - Clinical Specialist  
[robert.campbell@supplychain.nhs.uk](mailto:robert.campbell@supplychain.nhs.uk)

**Care Pathway Team** - first point of contact  
[cpt.vbhenquiries@supplychain.nhs.uk](mailto:cpt.vbhenquiries@supplychain.nhs.uk)

**Category Manager** - Briony Edwards  
[briony.edwards@supplychain.nhs.uk](mailto:briony.edwards@supplychain.nhs.uk)